Myelofibrosis : diagnosis and treatment
Copyright: © 2022 Permanyer..
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines. In recent years, important progress has been made in the knowledge of the molecular biology and the prognostic assessment of MF. Conventional treatment has limited impact on the patients' survival; it includes a wait-and-see approach for asymptomatic patients, erythropoiesis-stimulating agents, androgens, or immunomodulatory agents for anemia, cytoreductive drugs such as hydroxyurea for the splenomegaly and constitutional symptoms, and splenectomy or radiotherapy in selected patients. The discovery of the Janus kinase (JAK) 2 mutation triggered the development of molecular targeted therapy of MF. The JAK inhibitors are effective in both JAK2-positive and JAK2-negative MF; one of them, ruxolitinib, is the current best available therapy for MF splenomegaly and constitutional symptoms. Although ruxolitinib has changed the therapeutic scenario of MF, there is no clear indication of a disease-modifying effect. Allogeneic stem cell transplantation remains the only curative therapy of MF, but due to its associated morbidity and mortality, it is usually restricted to eligible high- and intermediate-2-risk MF patients. To improve current therapeutic results, the combination of JAK inhibitors with other agents is currently being tested, and newer drugs are being investigated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:158 |
|---|---|
| Enthalten in: |
Gaceta medica de Mexico - 158(2022), Supl 1 vom: 24., Seite 26-37 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Mielofibrosis: diagnóstico y tratamiento |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 21.09.2023 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.24875/GMM.M22000804 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362306680 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362306680 | ||
| 003 | DE-627 | ||
| 005 | 20231226090949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.24875/GMM.M22000804 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362306680 | ||
| 035 | |a (NLM)37734057 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barranco-Lampón, Gilberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myelofibrosis |b diagnosis and treatment |
| 246 | 3 | 3 | |a Mielofibrosis: diagnóstico y tratamiento |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2022 Permanyer. | ||
| 520 | |a Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines. In recent years, important progress has been made in the knowledge of the molecular biology and the prognostic assessment of MF. Conventional treatment has limited impact on the patients' survival; it includes a wait-and-see approach for asymptomatic patients, erythropoiesis-stimulating agents, androgens, or immunomodulatory agents for anemia, cytoreductive drugs such as hydroxyurea for the splenomegaly and constitutional symptoms, and splenectomy or radiotherapy in selected patients. The discovery of the Janus kinase (JAK) 2 mutation triggered the development of molecular targeted therapy of MF. The JAK inhibitors are effective in both JAK2-positive and JAK2-negative MF; one of them, ruxolitinib, is the current best available therapy for MF splenomegaly and constitutional symptoms. Although ruxolitinib has changed the therapeutic scenario of MF, there is no clear indication of a disease-modifying effect. Allogeneic stem cell transplantation remains the only curative therapy of MF, but due to its associated morbidity and mortality, it is usually restricted to eligible high- and intermediate-2-risk MF patients. To improve current therapeutic results, the combination of JAK inhibitors with other agents is currently being tested, and newer drugs are being investigated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Androgens | |
| 650 | 4 | |a Andrógenos | |
| 650 | 4 | |a Anemia | |
| 650 | 4 | |a Cytokine | |
| 650 | 4 | |a Hidroxiurea | |
| 650 | 4 | |a Hydroxyurea | |
| 650 | 4 | |a Inhibidores de la cinasa de Janus | |
| 650 | 4 | |a Janus kinase inhibitors | |
| 650 | 4 | |a Mielofibrosis | |
| 650 | 4 | |a Myelofibrosis | |
| 650 | 4 | |a Radiation therapy | |
| 650 | 4 | |a Radioterapia | |
| 650 | 4 | |a Ruxolitinib | |
| 650 | 4 | |a Splenectomy | |
| 650 | 4 | |a Splenomegaly | |
| 700 | 1 | |a Martínez-Castro, Raúl |e verfasserin |4 aut | |
| 700 | 1 | |a Arana-Luna, Luara |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez-Vera, José Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas-Castillejos, Flavio |e verfasserin |4 aut | |
| 700 | 1 | |a Peñaloza-Ramírez, Rosalinda |e verfasserin |4 aut | |
| 700 | 1 | |a Carballo-Zarate, Adrián Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Olarte-Carrillo, Irma |e verfasserin |4 aut | |
| 700 | 1 | |a Minamy, Jaime Israel-García |e verfasserin |4 aut | |
| 700 | 1 | |a López-Salazar, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Navarrete, Juan José |e verfasserin |4 aut | |
| 700 | 1 | |a Espinosa-Partida, Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Ventura-Enríquez, Yanet |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Contreras, Josué Isel |e verfasserin |4 aut | |
| 700 | 1 | |a Aguirre-Reyes, Oyuky Gissell |e verfasserin |4 aut | |
| 700 | 1 | |a Anaya-Cuéllar, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilar-Luévano, Jocelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz-Ramírez, Hugo Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera-Olivares, Wilfrido |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilar-Hidalgo, José Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Alcívar-Cedeño, Luisa Ma |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Caballero, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Galaz-Cordero, Lourdes Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Peña-Celaya, José Antonio de la |e verfasserin |4 aut | |
| 700 | 1 | |a Báez-Islas, Pamela Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Bates-Martín, Ramón Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Cano-León, Ana Ma de la Luz |e verfasserin |4 aut | |
| 700 | 1 | |a Espitia-Ríos, Ma Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Barbosa, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Morales-Adrián, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Pacheco, Martín Jacobo |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado-López, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Neme-Yunes, Yvette |e verfasserin |4 aut | |
| 700 | 1 | |a Moralws-Hernández, Alba Edna |e verfasserin |4 aut | |
| 700 | 1 | |a Mújica-Martínez, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Lizardi, Alejandra Betsabé |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Gómez, Karen Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Barragán-Ibáñez, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Adolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Flores-Ordúñez, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez-Hoyos, Paulina |e verfasserin |4 aut | |
| 700 | 1 | |a Rosales-López, Ma de Los Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Acosta-Maldonado, Brenda Lizeth |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Ochoa, Marco Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Garzón-Velásquez, Katheryn Betsabé |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Ruiz, Eleazar |e verfasserin |4 aut | |
| 700 | 1 | |a McNally-Guillén, Bosco Martín |e verfasserin |4 aut | |
| 700 | 1 | |a Saucedo-Montes, Erick Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilar-Andrade, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Vivas-Arteaga, Cindy Lissette |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra-Alarcón, Lidia Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Milán-Salvatierra, Andrea Iracema |e verfasserin |4 aut | |
| 700 | 1 | |a Campa-Monroy, Dafne Itzel |e verfasserin |4 aut | |
| 700 | 1 | |a Cota-Rangel, Xóchitl |e verfasserin |4 aut | |
| 700 | 1 | |a Estrada-Domínguez, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a García-Camacho, Alinka Socorro |e verfasserin |4 aut | |
| 700 | 1 | |a García-Castillo, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Banda-García, Luisa Iztacihuatl |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Sánchez, Vania |e verfasserin |4 aut | |
| 700 | 1 | |a Meillón-García, Luis Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Urbina-Escalante, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Ramírez, Mario Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Loera-Fragoso, Sergio José |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Coronel, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Zapata-Canto, Nidia |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Cortés, Sue Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Medina-Coral, Jesús Emanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Mójica-Balderas, Liliana |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Zúñiga, Juan Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez, Fernando Jacobo |e verfasserin |4 aut | |
| 700 | 1 | |a López-Arroyo, José Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Zazueta-Pozos, Juan Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Martínez, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Rodelo, Hilda |e verfasserin |4 aut | |
| 700 | 1 | |a Tapia-Enríquez, Ana Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano-Mercedes, Emely Johanny |e verfasserin |4 aut | |
| 700 | 1 | |a Salazar-Ramírez, Óscar |e verfasserin |4 aut | |
| 700 | 1 | |a Vilchis-González, Shendel Paulina |e verfasserin |4 aut | |
| 700 | 1 | |a Tepepa-Flores, Fredy |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarado-Ibarra, Martha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gaceta medica de Mexico |d 1945 |g 158(2022), Supl 1 vom: 24., Seite 26-37 |w (DE-627)NLM000276057 |x 0016-3813 |7 nnns |
| 773 | 1 | 8 | |g volume:158 |g year:2022 |g number:Supl 1 |g day:24 |g pages:26-37 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.24875/GMM.M22000804 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 158 |j 2022 |e Supl 1 |b 24 |h 26-37 | ||